中文
About Us
Our Focus
Our Focus
Pipeline
Leadership
Investors
News
Current Openings
Contact Us
中文
Current Location：
Home
>
News
2023
04-20
NeuroFront announces Exclusive Agreement for Commercialization of Relivion® with Jings in Taiwan
2022
07-21
Novaremed enters into an exclusive option and license agreement with NeuroFront for the non-opioid neuropathic pain treatment, NRD.E1, for Greater China and Singapore
2021
07-08
NeuroFront Announces Exclusive Licensing Agreement for Development and Commercialization of Neurolief's Relivion® in Greater China and South Korea
<
1
>
